Published: November 2019
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease
Roots Analysis has announced the addition of “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers” report to its list of offerings.
Advances in the field of biotechnology have enabled the development of several non-invasive approaches for cancer diagnosis with applications ranging from early diagnosis to patient and recurrence monitoring. Leveraging an array of versatile genomic tools, liquid biopsies have emerged as a powerful diagnostic solution, especially in cases where conventional diagnostic tests are inconclusive or the clinical condition is related to an organ that is not amenable to biopsy access.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link
Close to 300 liquid biopsy-based diagnostics are currently available / under development
Nearly 60% such solutions are available for commercial use, while the rest are either available for research purposes only or under development. Presently, majority of these tests are being developed for the isolation and analysis of cell-free DNA (cfDNA); other popular tumor markers analyzed via this method include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes.
North America is currently a hub of diagnostics development activity; over 50% of developers are based in this region
Recent reports indicate that there are 70 small-sized companies / start-ups, 39 mid-sized players and 6 large and very large business entities based in this part of the world.
USD 3+ billion was invested by both private and public investors, between 2015 and 2019
More than USD 2 billion was raised through venture capital financing alone, representing nearly 80% of the total capital raised. It is worth highlighting that GRAIL raised a total of USD 900 million in its series B financing round.
Partnership activity in this domain has increased at an annualized rate of 74%
In fact, around 80% of the deals reported in the study were established post 2016; the maximum partnership activity was observed in 2018. Majority of these agreements (80+) were observed to be either distribution & supply agreements and R&D agreements.
Several mergers and acquisitions inked between 2016 and 2019
Recent examples include (in reverse chronological order) the acquisition of Bellwether Bio by Guardant Health (2019), MolecularMD by ICON (2019) and Exosome Diagnostics by Bio-Techne (2018).
Currently, tests intended for patient monitoring have captured more than 60% of the overall market share
Given the challenges related to repeatedly performing invasive biopsies, liquid biopsy is expected to be widely adopted for patient monitoring purposes. However, ongoing efforts to address the high unmet need for early cancer detection are likely to result in an increase in the share of early diagnosis-focused tests, in the foreseen future.
Tests for prostate, breast, lung and colorectal cancer are anticipated to capture nearly 70% of the current market share
By 2030, the market is expected to expand significantly as liquid biopsies for other indications, such as bladder cancer, gastric cancer, melanoma, ovarian cancer and pancreatic cancer will likely get introduced.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following industry experts:
The research includes detailed profiles of key players (listed below), featuring an overview of the companies, their financial information (if available), a description of product(s) offered and an informed future outlook.
For additional details, please visit
or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry